American College of Neuropsychopharmacology Inc. Neuropsychopharmacology
subscribe to npp
SEARCH
Advanced search
My Account E-alerts Subscribe Register Help
Journal home
Current Issue
Advance Online Publication
Archive
Online sample issue FREE!
Author index
Keyword index
For authors
Editorial Board
Instructions for authors
Aims and scope
Indexed in
Author queries
Online Submission
Customer Services
Subscription information
Journal prices
Order sample issue
Purchase articles,
reprints & permissions
Advertising
Contact NPG
nature.com
Neuropsychopharmacology (1996) 15 562-566.

The D2 Receptor Occupancy Profile of Loxapine Determined Using PET

Shitij Kapur MD, FRCPC1,2, Robert B Zipursky MD, FRCPC1, Corey Jones B.Sc2, Gary J Remington MD, Ph.D, FRCPC1, Alan A Wilson Ph.D2, Jean DaSilva Ph.D2 and Sylvain Houle MD, Ph.D, FRCPC2
1From the Schizophrenia Division, The Clarke Institute of Psychiatry, Department of Psychiatry, University of Toronto, Ontario, Canada
2The PET Centre, The Clarke Institute of Psychiatry, Department of Psychiatry, University of Toronto, Ontario, Canada

Correspondence: Dr Shitij Kapur, PET Centre, The Clarke Institute of Psychiatry, 250 College Street, Toronto, ON, M5T 1R8, Canada

ABSTRACT

Positron emission tomography (PET) studies of typical neuroleptics suggest that 60% to 80% of striatal D2 occupancy may be sufficient for optimal clinical treatment of psychosis. Therefore, striatal D2 occupancy may be used as an index to determine the optimal dose range. Toward this end, we determined the in vivo D2 profile of loxapine, using [11C]-raclopride and PET. Seven patients selected from a clinical population were scanned while taking steady-state oral loxapine from 10 to 100 mg/day. Their D2 receptor occupancy was estimated by comparing them to age-matched data from neuroleptic-naive patients. The D2 receptor occupancy ranged from 52% to 90%, and there was a very strong relationship between dose and D2 occupancy, suggesting that 15 to 30 mg/day of loxapine would produce, the putatively optimal, 60% to 80% striatal D2 blockade. This dose range is much lower than that used in most clinical settings and points to the potential efficacy of loxapine at lower doses. Ó American College of Neuropsychopharmacology

Keywords: Loxapine; Dopamine receptors; Positron emission tomography; [11C]-Raclopride; Schizophrenia; Antipsychotics
  top go to top
Article Links
Send to a friend Send to a friend
Download PDF Download PDF
 Next Article Next Article
 Previous Article Previous Article
 Table of Contents Table of Contents
Privacy Policy Copyright © 1996 by the American College of Neuropsychopharmacology